Research programme: gene therapy - NanoCor Therapeutics

Drug Profile

Research programme: gene therapy - NanoCor Therapeutics

Alternative Names: BNP-CHF; Carfostin; Intracellular genetic protein therapy - NanoCor Therapeutics

Latest Information Update: 21 Apr 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator NanoCor Therapeutics
  • Class Gene therapies
  • Mechanism of Action Protein phosphatase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Heart failure

Most Recent Events

  • 21 Apr 2016 Preclinical development is ongoing in USA
  • 20 Apr 2016 US FDA approves IND application for Carfostin® in Heart failure
  • 20 Apr 2016 NanoCor plans a phase I trial for Heart failure in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top